Sermorelin

What is sermorelin?

Growth hormone release is stimulated by GHRH from the hypothalamus. Sermorelin is a 29-amino-acid synthetic analog of human GHRH and is described as the shortest synthetic peptide carrying the full biological activity of GHRH. When given into a vein or under the skin, it specifically stimulates growth hormone release from the anterior pituitary. ^[2]

Sermorelin’s effect is short-lived: the table in a 2026 review gives its disappearance half-life from blood as about 4.3 ± 1.4 minutes. ^[8] Sermorelin is not growth hormone itself; it stimulates the body’s own release. According to the review, the effect of GHRH analogs is subject to physiological regulatory loops such as somatostatin and IGF-1 feedback. The same review writes that in off-label use sermorelin is presented as a “physiological” route to body composition goals, but that clinically meaningful benefit in healthy people remains uncertain. ^[8]

Two more substances act through a similar pathway: CJC-1295, a longer-acting GHRH analog, and tesamorelin, which is licensed for HIV-associated lipodystrophy. Both are covered in separate guides: CJC-1295, Tesamorelin.

Why was Geref withdrawn from the market?

The FDA’s 2013 Federal Register notice summarizes the product’s official history: ^[1]

• Diagnostic Geref (NDA 19-863) was approved on December 28, 1990. Its indication was to assess the ability of somatotroph cells in the pituitary to secrete growth hormone.
• Therapeutic Geref (NDA 20-443) was approved on September 26, 1997. Its indication was the treatment of idiopathic growth hormone deficiency in children with growth failure.
• By letters dated July 11, 2008, and December 2, 2008, the manufacturer notified the FDA that production of both products had been discontinued; the FDA moved the products to the “discontinued products” section of the Orange Book. Both approvals were withdrawn as of June 18, 2009.
• On a petition submitted in 2012, the FDA reviewed its records and postmarketing adverse event data and determined that both products were not withdrawn from sale for reasons of safety or effectiveness. If other legal conditions are met, this determination allows generic (ANDA) applications to be approved; it is not itself a drug approval.

The FDA notice does not state that the withdrawal rested on a commercial reason; it states only that safety and effectiveness were not the cause. ^[1] The 2026 review interprets this determination as supporting a non-clinical explanation, such as commercial or access-related decisions, rather than a new safety signal. ^[8]

What was sermorelin used for in children?

Sermorelin’s licensed use had two legs: a diagnostic test and treatment of growth hormone deficiency in children.

Diagnostic test: According to the 1999 review, the hormone response measured with intravenously administered sermorelin is a rapid and relatively specific test for growth hormone deficiency; false-positive responses in children without deficiency are less common than with other stimulation tests. However, if the deficiency originates in the hypothalamus, the pituitary may respond normally to sermorelin; in this case, a low response on other stimulation tests is needed for diagnosis. The review concludes that the test is appropriate for use together with conventional tests. ^[2]

Treatment: Most of the evidence comes from studies run by the international study group that bore the drug’s name.

The review writes that data showing sermorelin accelerates growth in some prepubertal children are “limited.” The effect of long-term treatment on final adult height had not been determined; at the recommended dose, sermorelin had not been compared directly with somatropin (growth hormone), and with other administration schedules the increase in growth velocity was lower than that seen with once-daily somatropin. ^[2] The result of the Neyzi study supports this direction as well: although growth velocity at the high dose approached that of growth hormone, the height gain relative to bone age was seen only in the growth hormone group. ^[4]

What is known in adults and in aging?

Growth hormone and IGF-1 levels fall with age; because this decline was thought to be associated with muscle loss and fat gain, GHRH trials were carried out in older adults in the 1990s. All the published studies are small and short.

The common finding of these three studies is that sermorelin can increase growth hormone secretion in older adults. However, the findings on muscle and fat are small, inconsistent, and vary by sex; the placebo period in the Khorram study is not a parallel control group but a period applied first in the same people. ^[6] The authors of the Vittone study interpret single nightly doses as less effective than multiple daily doses; IGF-1 did not rise in this study. ^[7]

What do the anti-aging claims rest on?

Claims such as “slows aging,” “rejuvenates,” or “gives energy” rest on the observation that growth hormone and IGF-1 fall with age and that sermorelin can raise these levels. The adult studies above lasted between 2 and 20 weeks and involved at most 19 people; none measured an outcome such as disease, frailty, falls, or lifespan. ^{[5] [6] [7]} The 2026 review likewise states that human data for sermorelin are limited and largely indirect, and that clinically meaningful benefit in healthy people remains uncertain. ^[8] A rise in a hormone level does not mean that aging has slowed.

What are the risks and unknowns?

In the pediatric studies of the licensed period, single intravenous doses and daily subcutaneous administration were well tolerated; the most commonly reported side effects were transient facial flushing and pain at the injection site. ^[2] In the 110-child study, no adverse change was seen in general biochemical and hormonal tests. ^[3] In the older adult studies, a transient blood lipid elevation was reported; no serious side effects were seen in the other two studies. ^{[6] [7]}

These data are limited. The longest adult study lasted 20 weeks; the safety of use lasting months or years was not examined. ^[6] The 2026 review lists side effects reported with off-label use of peptides that stimulate the growth hormone-IGF-1 axis at the class level: impaired blood sugar, fluid retention, muscle and joint pain, injection site reactions; it also draws attention to a biologically plausible but unproven concern about cell proliferation (cancer) related to prolonged IGF-1 elevation. ^[8] The same review stresses that in unsupervised supply chains, the contents and purity of products are uncertain. ^[8]

General peptide side effects and injection-related risks are in a separate guide: Peptide side effects

FDA, WADA, and Türkiye: what is the legal status?

United States: former approval, compounding lists, and warning letters

In the US today, sermorelin is a drug whose approval was withdrawn but which was officially determined not to have been withdrawn for safety reasons. ^[1] For bulk substances used in drugs prepared in pharmacies (compounding), the FDA keeps two separate nomination lists:

• 503A (pharmacies): In the category document dated May 14, 2026, sermorelin appears in none of the category 1 (under evaluation), category 2 (significant safety risk), or category 3 (nominated without sufficient support) lists. ^[9]
• 503B (outsourcing facilities): In the category document dated March 21, 2025, sermorelin acetate is in category 1 and carries the “component of FDA-approved drugs” marking. According to a footnote of the same document, the FDA does not intend to take action against facilities filling orders that are essentially copies of an approved drug that has been discontinued and is no longer marketed, because of this copy condition. ^[10]

These lists are not a drug approval; they concern whether the bulk substance can be used in compounding. Products sold “for research purposes” are a separate matter: in a December 2024 warning letter, the FDA characterized the products of a company selling various peptides online, including sermorelin, as unapproved new drugs. According to the letter, despite the “for research use only” and “not for human use” statements on the product labels, the claims on the website showed that the products were being sold to be used as drugs in humans. ^[11] What this label means is in a separate guide: What does research peptide mean?

Sport (WADA)

In WADA’s list effective from January 1, 2026, sermorelin is named, together with CJC-1293, CJC-1295, and tesamorelin, among GHRH and its analogs under the heading S2.2.4 “growth hormone releasing factors.” Substances in class S2 are prohibited at all times, in and out of competition, and none of the substances in this class is a “specified substance.” ^[12]

Türkiye

No product with sermorelin as the active ingredient is on the TİTCK (Turkish Medicines and Medical Devices Agency) Licensed Human Medicinal Products List dated October 16, 2026. ^[13] Article 19 of Law No. 1262 on Pharmaceutical and Medicinal Preparations (İspençiyari ve Tıbbi Müstahzarlar Kanunu) punishes with one to five years of imprisonment those who manufacture unlicensed preparations and those who knowingly sell, offer for sale, or have such manufactured preparations sold; the same penalty is provided for those who sell, market, or advertise a product that is not a preparation with the claim that it diagnoses or treats diseases. Importing preparations made abroad without a license for commercial purposes is treated as smuggling. ^[14]

The general legal framework for peptides: Are peptides legal?

Evidence table: claim, population, and limits

Limits of this guide

This page summarizes published human studies on sermorelin and the decisions of official bodies. It gives no dose, course, preparation, administration technique, or product sourcing information; the administrations in the studies are only the description of that study. Growth hormone deficiency is a diagnosis that must be confirmed with laboratory tests and followed by a physician.